PE20220711A1 - Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6) - Google Patents
Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6)Info
- Publication number
- PE20220711A1 PE20220711A1 PE2022000460A PE2022000460A PE20220711A1 PE 20220711 A1 PE20220711 A1 PE 20220711A1 PE 2022000460 A PE2022000460 A PE 2022000460A PE 2022000460 A PE2022000460 A PE 2022000460A PE 20220711 A1 PE20220711 A1 PE 20220711A1
- Authority
- PE
- Peru
- Prior art keywords
- optionally substituted
- halogen atoms
- group
- isoindol
- substituents selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019177815 | 2019-09-27 | ||
| PCT/JP2020/037386 WO2021060567A1 (en) | 2019-09-27 | 2020-09-24 | 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220711A1 true PE20220711A1 (es) | 2022-05-04 |
Family
ID=73040188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000460A PE20220711A1 (es) | 2019-09-27 | 2020-09-24 | Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6) |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11453661B2 (enExample) |
| EP (1) | EP4034536A1 (enExample) |
| JP (1) | JP7602546B2 (enExample) |
| KR (1) | KR20220070465A (enExample) |
| CN (1) | CN114846012B (enExample) |
| AR (1) | AR120040A1 (enExample) |
| AU (1) | AU2020353984B2 (enExample) |
| BR (1) | BR112022005595A2 (enExample) |
| CA (1) | CA3156060A1 (enExample) |
| CL (1) | CL2022000763A1 (enExample) |
| CO (1) | CO2022005059A2 (enExample) |
| EC (1) | ECSP22026524A (enExample) |
| IL (1) | IL291413B2 (enExample) |
| MX (1) | MX2022003490A (enExample) |
| PE (1) | PE20220711A1 (enExample) |
| PH (1) | PH12022550748A1 (enExample) |
| TW (1) | TWI882012B (enExample) |
| WO (1) | WO2021060567A1 (enExample) |
| ZA (1) | ZA202204666B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| CN114727974A (zh) | 2019-07-30 | 2022-07-08 | 艾科尼佐治疗股份有限公司 | Hdac6抑制剂及其用途 |
| CN114846012B (zh) * | 2019-09-27 | 2024-01-26 | 武田药品工业株式会社 | 可用作hdac6抑制剂的2-异吲哚-1,3,4-噁二唑衍生物 |
| KR20220119653A (ko) | 2019-12-20 | 2022-08-30 | 테나야 테라퓨틱스, 인코포레이티드 | 플루오로알킬-옥사디아졸 및 이의 용도 |
| WO2022169985A1 (en) | 2021-02-03 | 2022-08-11 | Eikonizo Therapeutics, Inc. | Hdac6 inhibitors and uses thereof |
| EP4326263A1 (en) | 2021-04-23 | 2024-02-28 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy |
| US20240252502A1 (en) | 2021-05-04 | 2024-08-01 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for treatment of metabolic disease and hfpef |
| CN114166824B (zh) * | 2021-12-08 | 2024-01-23 | 桂林医学院 | 一种辅剂示踪分析保健品中药物含量的方法 |
| AU2023250964A1 (en) | 2022-04-08 | 2024-11-07 | Eikonizo Therapeutics, Inc. | Oxadiazole hdac6 inhibitors and uses thereof |
| EP4509506A4 (en) * | 2022-04-15 | 2026-03-25 | Suzhou Genhouse Bio Co Ltd | OXADIAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING IT AND ITS USAGE |
| EP4685143A1 (en) * | 2023-03-21 | 2026-01-28 | Vivozon,Inc. | Double regulator for mglur5 and hdac6 and use thereof |
| KR102972943B1 (ko) * | 2023-08-22 | 2026-06-02 | 전남대학교산학협력단 | 신경세포로의 분화 촉진용 조성물 |
| CN121969616A (zh) * | 2023-09-28 | 2026-05-01 | 勤浩医药(苏州)股份有限公司 | 一种hdac6抑制剂的结晶形式及其制备方法 |
| WO2025215092A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
| CN119823019A (zh) * | 2025-01-06 | 2025-04-15 | 沈阳药科大学 | 一种具有治疗特发性肺纤维化作用的吲哚类化合物及其制备方法和应用 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| US20040142859A1 (en) | 2002-05-02 | 2004-07-22 | Steffan Joan S. | Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors |
| DE60227658D1 (de) | 2001-05-02 | 2008-08-28 | Univ California | Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren |
| US20050227915A1 (en) | 2001-05-02 | 2005-10-13 | Steffan Joan S | Methods and reagents for treating neurodegenerative diseases and motor deficit disorders |
| EP1443928B1 (en) | 2001-10-16 | 2011-07-27 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain |
| MXPA04008577A (es) | 2002-03-04 | 2005-07-13 | Aton Pharma Inc | Metodos para inducir diferenciacion terminal. |
| AU2003244713A1 (en) | 2002-03-26 | 2003-10-08 | Exonhit Therapeutics S.A. | Histone deacetylase: novel molecular target of neurotoxicity |
| WO2003083067A2 (en) | 2002-03-28 | 2003-10-09 | Brigham And Women's Hospital, Inc. | Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease |
| ITMI20040876A1 (it) | 2004-04-30 | 2004-07-30 | Univ Degli Studi Milano | Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari |
| US20060018921A1 (en) | 2004-07-16 | 2006-01-26 | Baylor College Of Medicine | Histone deacetylase inhibitors and cognitive applications |
| GT200500321A (es) | 2004-11-09 | 2006-09-04 | Compuestos y composiciones como inhibidores de proteina kinase. | |
| CN101056632B (zh) * | 2004-11-09 | 2011-12-07 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
| US20060135612A1 (en) | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| SG171690A1 (en) | 2005-03-22 | 2011-06-29 | Harvard College | Treatment of protein degradation disorders |
| CN101267779A (zh) | 2005-07-27 | 2008-09-17 | 福罗里达大学研究基金会有限公司 | 使用热休克治疗眼睛疾病 |
| CA2621560A1 (en) | 2005-09-07 | 2007-03-15 | Braincells, Inc. | Modulation of neurogenesis by hdac inhibition |
| WO2007049262A1 (en) | 2005-10-27 | 2007-05-03 | Berand Limited | Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders |
| CA2626897A1 (en) | 2005-11-03 | 2007-05-18 | Joshua Close | Histone deacetylase inhibitors with aryl-pyrazolyl motifs |
| US20070207950A1 (en) | 2005-12-21 | 2007-09-06 | Duke University | Methods and compositions for regulating HDAC6 activity |
| GB0612273D0 (en) | 2006-06-21 | 2006-08-02 | Friedrich Miescher Inst For Bi | Prevention of muscle atrophy |
| US8088951B2 (en) | 2006-11-30 | 2012-01-03 | Massachusetts Institute Of Technology | Epigenetic mechanisms re-establish access to long-term memory after neuronal loss |
| WO2008073733A1 (en) | 2006-12-08 | 2008-06-19 | Kalypsys, Inc. | Salts of inhibitors of histone deacetylase for the treatment of disease |
| MX2009006327A (es) | 2006-12-15 | 2009-06-23 | Novartis Ag | Compuestos heterociclicos y metodos de uso de los mismos. |
| WO2008126932A2 (en) | 2007-04-09 | 2008-10-23 | Riken | Epigenetical regulation of brain plasticity |
| WO2009002495A1 (en) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| EP2195029A2 (en) | 2007-08-24 | 2010-06-16 | Oryzon Genomics SA | Treatment and prevention of neurodegenerative diseases |
| US20090136461A1 (en) | 2007-11-28 | 2009-05-28 | Moon Suk Kim | Neuronal differentiation method of adult stem cells using small molecules |
| AU2013203735A1 (en) * | 2007-12-04 | 2013-05-02 | F. Hoffmann-La Roche Ag | Isoxazolo-pyridine derivatives |
| AU2010333767A1 (en) * | 2009-12-22 | 2012-07-05 | Celgene Corporation | (Methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses |
| KR101781663B1 (ko) | 2010-01-13 | 2017-09-25 | 템페로 파마슈티칼즈, 인크. | 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법 |
| EP2523664A4 (en) | 2010-01-13 | 2013-06-26 | Tempero Pharmaceuticals Inc | COMPOUNDS AND METHODS |
| WO2012018499A2 (en) | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
| CA2812855C (en) | 2010-10-08 | 2017-12-19 | Vib Vzw | Hdac inhibitors to treat charcot-marie-tooth disease |
| WO2012058128A2 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Caprolactam mglur5 receptor modulators |
| WO2012118782A1 (en) | 2011-02-28 | 2012-09-07 | Repligen Corporation | Histone deacetylase inhibitors |
| US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US8957066B2 (en) * | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| WO2012149540A1 (en) | 2011-04-28 | 2012-11-01 | The Broad Institute Inc | Inhibitors of histone deacetylase |
| US20140235649A1 (en) | 2011-05-24 | 2014-08-21 | Lixte Biotechnology, Inc. | Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function |
| WO2013006408A1 (en) | 2011-07-01 | 2013-01-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| EA201490228A1 (ru) | 2011-07-08 | 2014-08-29 | Новартис Аг | Новые производные трифторметилоксадиазола и их применение для лечения заболевания |
| WO2013009830A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009827A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009810A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| EP2734500A4 (en) | 2011-07-20 | 2015-04-08 | Gen Hospital Corp | SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS |
| WO2013066839A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066833A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| WO2013066835A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066831A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066838A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| CA2856334A1 (en) | 2011-11-28 | 2013-06-06 | Christina Hebach | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| WO2013149091A1 (en) | 2012-03-29 | 2013-10-03 | The Regents Of The University Of Colorado, A Body Corporate | Composition and method for treating neurodegenerative disease |
| US20150119327A1 (en) | 2012-04-25 | 2015-04-30 | The Regents Of The University Of California | Drug screening platform for rett syndrome |
| US20150184154A1 (en) | 2012-07-05 | 2015-07-02 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear | New treatment for neurodegenerative diseases |
| CN104894060B (zh) | 2014-03-03 | 2018-11-06 | 中国科学院上海生命科学研究院 | 诱导体细胞转分化为神经干细胞的方法及其应用 |
| TR201816176T4 (tr) | 2014-03-12 | 2018-11-21 | Chong Kun Dang Pharmaceutical Corp | Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler. |
| EP3187497A4 (en) | 2014-08-26 | 2018-02-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JPWO2016039398A1 (ja) | 2014-09-09 | 2017-06-15 | 国立大学法人大阪大学 | 含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物 |
| TW201629026A (zh) | 2015-02-02 | 2016-08-16 | 佛瑪治療公司 | 作為ｈｄａｃ抑制劑的３－烷基雙環［４，５，０］異羥肟酸 |
| CN107848695A (zh) | 2015-06-30 | 2018-03-27 | Wm.雷格利 Jr.公司 | 用于糖果产品的包装和用于形成该包装的方法 |
| US10357484B2 (en) | 2015-07-17 | 2019-07-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| CN108026088B (zh) * | 2015-07-17 | 2021-02-12 | 武田药品工业株式会社 | 用作hdac抑制剂的噁二唑衍生物 |
| HRP20230052T1 (hr) | 2015-07-27 | 2023-03-03 | Chong Kun Dang Pharmaceutical Corp. | Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži |
| NZ739211A (en) | 2015-07-27 | 2019-05-31 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same |
| BR112017027798B1 (pt) | 2015-07-27 | 2023-12-19 | Chong Kun Dang Pharmaceutical Corp | Compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos |
| HRP20220003T1 (hr) | 2015-08-04 | 2022-04-01 | Chong Kun Dang Pharmaceutical Corp. | Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži |
| WO2017033946A1 (ja) | 2015-08-25 | 2017-03-02 | 武田薬品工業株式会社 | 複素環化合物 |
| FI3362445T3 (fi) | 2015-10-12 | 2023-03-21 | Chong Kun Dang Pharmaceutical Corp | Oksadiatsoliamiinijohdannaisyhdisteitä histonideasetylaasi 6:n inhibiittoreina ja niitä käsittävä farmaseuttinen koostumus |
| WO2017222952A1 (en) * | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| US20180016314A1 (en) | 2016-07-12 | 2018-01-18 | Children's Hospital Medical Center | Treatment of disease via transcription factor modulation |
| US10357493B2 (en) * | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| WO2018215597A1 (en) | 2017-05-24 | 2018-11-29 | Orphazyme A/S | Heat shock protein inducers and frontotemporal disorders |
| US10435399B2 (en) | 2017-07-31 | 2019-10-08 | Takeda Pharmaceutical Company Limited | HDAC6 inhibitory heterocyclic compound |
| WO2019032652A1 (en) | 2017-08-09 | 2019-02-14 | Children's Hospital Medical Center | METHODS OF TREATING DISEASES AND NERVE INJURIES |
| US20200216563A1 (en) | 2017-08-10 | 2020-07-09 | Friedrich Miescher Institute For Biomedical Research | Hdac6 and protein aggregation |
| JP6910984B2 (ja) | 2018-03-30 | 2021-07-28 | 株式会社ホンダアクセス | 脱出ハンマー収容具 |
| KR102316234B1 (ko) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| RS66346B1 (sr) | 2018-10-22 | 2025-01-31 | Alumis Inc | Inhibitori tyk2 i njihova upotreba |
| EP3919055A4 (en) | 2019-01-30 | 2022-11-09 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
| CN114846012B (zh) * | 2019-09-27 | 2024-01-26 | 武田药品工业株式会社 | 可用作hdac6抑制剂的2-异吲哚-1,3,4-噁二唑衍生物 |
-
2020
- 2020-09-24 CN CN202080068097.3A patent/CN114846012B/zh active Active
- 2020-09-24 MX MX2022003490A patent/MX2022003490A/es unknown
- 2020-09-24 PH PH1/2022/550748A patent/PH12022550748A1/en unknown
- 2020-09-24 KR KR1020227012924A patent/KR20220070465A/ko active Pending
- 2020-09-24 EP EP20800345.9A patent/EP4034536A1/en active Pending
- 2020-09-24 JP JP2022545275A patent/JP7602546B2/ja active Active
- 2020-09-24 TW TW109133124A patent/TWI882012B/zh active
- 2020-09-24 AU AU2020353984A patent/AU2020353984B2/en active Active
- 2020-09-24 US US17/030,504 patent/US11453661B2/en active Active
- 2020-09-24 PE PE2022000460A patent/PE20220711A1/es unknown
- 2020-09-24 WO PCT/JP2020/037386 patent/WO2021060567A1/en not_active Ceased
- 2020-09-24 IL IL291413A patent/IL291413B2/en unknown
- 2020-09-24 CA CA3156060A patent/CA3156060A1/en active Pending
- 2020-09-24 AR ARP200102652A patent/AR120040A1/es unknown
- 2020-09-24 BR BR112022005595A patent/BR112022005595A2/pt unknown
-
2022
- 2022-03-25 CL CL2022000763A patent/CL2022000763A1/es unknown
- 2022-04-04 EC ECSENADI202226524A patent/ECSP22026524A/es unknown
- 2022-04-22 CO CONC2022/0005059A patent/CO2022005059A2/es unknown
- 2022-04-26 ZA ZA2022/04666A patent/ZA202204666B/en unknown
- 2022-09-26 US US17/952,546 patent/US11958845B2/en active Active
-
2024
- 2024-04-15 US US18/635,839 patent/US12384770B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12384770B2 (en) | 2025-08-12 |
| CO2022005059A2 (es) | 2022-07-08 |
| AU2020353984B2 (en) | 2025-09-25 |
| TW202126643A (zh) | 2021-07-16 |
| US20240343721A1 (en) | 2024-10-17 |
| CN114846012B (zh) | 2024-01-26 |
| MX2022003490A (es) | 2022-04-25 |
| ZA202204666B (en) | 2023-11-29 |
| WO2021060567A1 (en) | 2021-04-01 |
| US20230183227A1 (en) | 2023-06-15 |
| TWI882012B (zh) | 2025-05-01 |
| US20210094944A1 (en) | 2021-04-01 |
| BR112022005595A2 (pt) | 2022-07-19 |
| AU2020353984A1 (en) | 2022-04-21 |
| AU2020353984A2 (en) | 2022-08-04 |
| PH12022550748A1 (en) | 2023-11-20 |
| IL291413B1 (en) | 2024-11-01 |
| JP7602546B2 (ja) | 2024-12-18 |
| CL2022000763A1 (es) | 2023-01-20 |
| US11453661B2 (en) | 2022-09-27 |
| EP4034536A1 (en) | 2022-08-03 |
| CA3156060A1 (en) | 2021-04-01 |
| JP2022552444A (ja) | 2022-12-15 |
| KR20220070465A (ko) | 2022-05-31 |
| ECSP22026524A (es) | 2022-05-31 |
| CN114846012A (zh) | 2022-08-02 |
| IL291413B2 (en) | 2025-03-01 |
| US11958845B2 (en) | 2024-04-16 |
| AR120040A1 (es) | 2022-01-26 |
| IL291413A (en) | 2022-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR120040A1 (es) | Compuesto heterocíclico | |
| AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
| PE20180529A1 (es) | Agonistas de triazol del receptor apj | |
| AR101177A1 (es) | Inhibidores de la syk | |
| AR087668A1 (es) | Derivados de oxazina y su uso en el tratamiento de enfermedades | |
| AR108118A1 (es) | Oxadiazoles sustituidos para combatir hongos fitopatógenos | |
| JP2014511892A5 (enExample) | ||
| RU2019106484A (ru) | Гетероциклическое соединение | |
| PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| JP2013545791A5 (enExample) | ||
| BR112015021027A8 (pt) | compostos terapêuticos, seus usos, e composições farmacêuticas | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| AR089424A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| BR112016028818A2 (pt) | composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo. | |
| BR112016028819A2 (pt) | composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos. | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| PE20190806A1 (es) | Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| JP2014502988A5 (enExample) | ||
| AR102217A1 (es) | Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii | |
| AR082620A1 (es) | Compuesto de quinolil amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar una enfermedad mediada por la inhibicion de la quinasa rip2 | |
| CO2020012353A2 (es) | Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos | |
| RU2014109747A (ru) | Морфолино-замещенные производные мочевины или карбамата в качестве ингибиторов mtor | |
| JP2014530197A5 (enExample) | ||
| MX385276B (es) | Tratamiento para la enfermedad de parkinson |